13F reference period
Q2 2026
Security Snapshot
LENZ Therapeutics, Inc. - Common Stock, $0.00001 par value per share (LENZ) Institutional Ownership
CUSIP: 52635N103
13F Institutional Holders and Ownership History from Q1 2024 to Q3 2026
Institutions Reporting
144
Shares (Excl. Options)
34.69M
Full value: 34,688,911 · shares · 30 Jun 2026Price
$5.68
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.00001 par value per share
- Symbol
- LENZ on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 34,688,911
- Total 13F value
- $197,028,598
- Portfolio coverage rank
- 0%
- Share change
- +1,539,791
- Value change
- +$1,703,824
- Number of holders
- 144
- Shares outstanding
- 31,503,388
- SEC-reported price per share
- $3.40
- Insider filing price
- $3.40
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- LENZ - LENZ Therapeutics, Inc. - Common Stock, $0.00001 par value per share is tracked under CUSIP 52635N103.
- 144 institutions reported positions in Q2 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 145 to 144 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$303.09M
Full value: $303,088,609 · USD · 31 Mar 2026.$197.03M
Full value: $197,028,598 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 144 institutions filings for Q2 2026.
Security key
52635N103
13F reference period
Q2 2026
13F holders
144
13D/G owners
10
CIK / CUSIP context first
Open Q2 2026 holders
LENZ full holder history
LENZ Therapeutics, Inc. SEC filings
LENZ Therapeutics, Inc. company facts
LENZ Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 52635N103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
10
Security
LENZ
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 6.7% | $7,176,472 | 2,110,727 | BML Investment Partners, L.P. | 02 Nov 2026 | |||
| BlackRock, Inc. | 5.8% | +18% | $16,515,263 | +$2,438,486 | 1,804,099 | +17% | BlackRock, Inc. | 31 Mar 2026 |
| FMR LLC | 5.7% | -51% | $8,202,730 | -$8,829,769 | 1,783,202 | -52% | FMR LLC | 31 Aug 2026 |
| BlackRock Portfolio Management LLC | 5.2% | $6,319,665 | 1,645,489 | BlackRock Portfolio Management LLC | 30 Sep 2026 | |||
| Squarepoint Ops LLC | 5.1% | $14,897,009 | 1,593,246 | Squarepoint Ops LLC | 01 Apr 2026 | |||
| Point72 Asset Management, L.P. | 4.8% | $63,244,042 | 1,357,751 | Steven A. Cohen | 30 Sep 2025 | |||
| MILLENNIUM MANAGEMENT LLC | 3.7% | -28% | $4,456,554 | -$1,703,979 | 1,159,987 | -28% | Millennium Management LLC | 30 Sep 2026 |
| Paradigm Biocapital Advisors LP | 3.8% | -28% | $50,001,813 | -$16,133,961 | 1,073,461 | -24% | Paradigm BioCapital Advisors LP | 30 Sep 2025 |
| Versant Venture Capital VI, L.P. | 3.4% | -18% | $48,936,901 | -$6,192,532 | 1,050,599 | -11% | Versant Venture Capital VI, L.P. | 05 Nov 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 0.2% | -96% | $239,812 | -$14,261,548 | 70,533 | -98% | RA Capital Management, L.P. | 29 Oct 2026 |
As of 30 Jun 2026,
144
institutional investors reported holding
shares of
LENZ Therapeutics, Inc. - Common Stock, $0.00001 par value per share (LENZ).
This represents
110%
of the company’s total
outstanding shares.
34.69M
Full value: 34,688,911 · shares · 30 Jun 202631.5M
Full value: 31,503,388 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
96%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 13% | 4,178,823 | 0% | 0.21% | $23,735,715 |
| Alpha Wave Global, LP | 11% | 3,612,211 | 0% | 0.33% | $20,517,358 |
| FMR LLC | 11% | 3,558,905 | -1.1% | 0% | $20,214,577 |
| Versant Venture Management, LLC | 8.4% | 2,656,888 | 0% | 9.3% | $15,091,124 |
| BlackRock, Inc. | 7.3% | 2,292,121 | +16% | 0% | $13,019,246 |
| Squarepoint Ops LLC | 5.5% | 1,747,096 | +16% | 0.02% | $9,923,505 |
| Aberdeen Group plc | 4.9% | 1,547,883 | +34% | 0.01% | $8,791,975 |
| MILLENNIUM MANAGEMENT LLC | 4.8% | 1,508,478 | +74% | 0.01% | $8,568,155 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 1,097,755 | +5.4% | 0% | $6,235,248 |
| 72 Investment Holdings, LLC | 3.2% | 1,017,751 | 0% | 12% | $5,780,826 |
| Blue Owl Capital Holdings LP | 2.4% | 756,722 | +49% | 0.65% | $4,298,181 |
| C WorldWide Group Holding A/S | 2.2% | 700,000 | 0% | 0.1% | $3,976,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 564,662 | +7.6% | 0% | $3,208,042 |
| Trexquant Investment LP | 1.6% | 497,526 | +132% | 0.02% | $2,825,948 |
| MARSHALL WACE, LLP | 1.6% | 493,099 | +208% | 0% | $2,800,801 |
| Qube Research & Technologies Ltd | 1.5% | 482,195 | 0% | $2,738,868 | |
| MORGAN STANLEY | 1.5% | 472,995 | -27% | 0% | $2,686,612 |
| PRIMECAP MANAGEMENT CO/CA/ | 1.5% | 472,200 | 0% | 0% | $2,682,096 |
| TANG CAPITAL MANAGEMENT LLC | 1.4% | 451,114 | 0% | 0.12% | $2,562,328 |
| Alyeska Investment Group, L.P. | 1.4% | 438,882 | -5.3% | 0.01% | $2,492,850 |
| STATE STREET CORP | 1.3% | 406,674 | +1.1% | 0% | $2,309,908 |
| CITADEL ADVISORS LLC | 1.2% | 363,229 | 0% | $2,063,141 | |
| TWO SIGMA INVESTMENTS, LP | 0.91% | 285,584 | -43% | 0% | $1,622,117 |
| Rock Springs Capital Management LP | 0.82% | 257,460 | 0% | 0.07% | $1,462,373 |
| BANK OF AMERICA CORP /DE/ | 0.81% | 255,410 | -53% | 0% | $1,450,729 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Headline period
Q2 2026
Rows shown
1-11 of 11
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 228,794 | $877,901 | -$449,339 | $3.84 | 23 |
| 2026 Q2 | 34,688,911 | $197,028,598 | +$1,703,824 | $5.68 | 144 |
| 2026 Q1 | 33,125,536 | $303,088,609 | -$46,524,940 | $9.15 | 145 |
| 2025 Q4 | 35,070,612 | $561,546,547 | -$86,155,656 | $16.00 | 161 |
| 2025 Q3 | 29,140,610 | $1,355,578,952 | +$224,909,861 | $46.58 | 166 |
| 2025 Q2 | 24,727,156 | $725,109,733 | +$107,969,187 | $29.31 | 113 |
| 2025 Q1 | 21,072,237 | $541,761,121 | +$29,092,976 | $25.71 | 105 |
| 2024 Q4 | 19,863,850 | $573,239,116 | +$35,341,897 | $28.87 | 94 |
| 2024 Q3 | 18,735,645 | $444,795,067 | -$1,423,016 | $23.74 | 78 |
| 2024 Q2 | 18,913,542 | $327,016,869 | +$45,118,057 | $17.29 | 63 |
| 2024 Q1 | 16,171,755 | $361,085,230 | +$360,723,016 | $22.33 | 54 |